Gut bacteria programmed to detect and treat early colorectal cancer
Engineering Native E. coli to Detect, Report, and Treat Colorectal Cancer
Researchers are programming common gut E. coli to spot and report early colorectal cancer for people at higher risk or with early lesions.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11187222 on NIH RePORTER |
What this research studies
If I signed up, the team would use modified E. coli that naturally live in the colon to sense chemical changes near early polyps and tumors. The bacteria would be engineered to send back a detectable signal or to release a therapy directly at the abnormal site. The work combines lab and animal testing with steps toward safe use in people who need better screening, such as those with genetic risks, inflammatory bowel disease, or younger adults. The goal is earlier, less invasive detection and blocking the progression from adenoma to cancer.
Who could benefit from this research
Good fit: People at elevated colorectal cancer risk—such as those with familial adenomatous polyposis, inflammatory bowel disease, a strong family history, or early lesions under surveillance—would be the most likely candidates.
Not a fit: People with advanced metastatic disease, those who cannot receive gut-colonizing bacterial therapies, or those without colorectal disease concerns are unlikely to benefit directly.
Why it matters
Potential benefit: Could enable earlier, less invasive detection of colorectal cancer and deliver targeted local treatments that prevent adenomas from progressing to invasive cancer.
How similar studies have performed: Engineered-bacteria approaches have shown promise in animal models and limited early human work for other gut conditions, but using native E. coli to detect and treat colorectal cancer remains largely experimental.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Zarrinpar, Amir — University of California, San Diego
- Study coordinator: Zarrinpar, Amir
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.